FDA Authorizes COVID-19 Boosters of Pfizer for Seniors and Those at High Risk

A vial of Pfizer-BioNTech COVID-19 vaccine in Los Angeles, Calif., on Aug. 23, 2021. Robyn Beck/AFP via Getty Images

The Food and Drug Administration on Wednesday authorized for emergency use a booster dose of the Pfizer-BioNTech vaccine for those aged 65 and older, as well as those aged 18–64 who are at high risk of severe COVID-19.

The third dose of the mRNA-based shot is authorized to be administered at least six months after the first two doses of the vaccine.